Month: November 2021

When we posted our first blog on immunotherapy at the start of the 2015 New Year, hopes were rosy that immunotherapies were bringing treatment for metastatic prostate cancer to the brink of a new treatment threshold. Since then, it was found that immunotherapy drugs that worked quite well for other metastatic cancers such as melanoma and certain lung cancers... keep reading

When a man is experiencing pelvic pain due to prostatitis (prostate inflammation) it’s important to rule out a bacterial infection. However, in most cases of chronic prostatitis, no cause can be found. It’s commonly recommended to patients to take over the counter nonsteroidal anti-inflammatory (NSAID) products such as ibuprofen or acetaminophen, which are cheap and readily available. keep reading

The term “liquid biopsy” is appearing with increasing frequency in published literature. The fact that it’s more common than ever does not mean we’ve finally replaced a needle extraction of tissue. However, a blood or urine sample is a far less invasive way to gather a large quantity of information to profile a patient’s prostate cancer (PCa), thanks to numerous biological clues that tumor cells release into the bloodstream. keep reading

“Introducing the ultimate technology in Precision Medicine for Prostate Focal Therapy.” “TSPA is the only technology designed for Prostate Focal Therapy” These bold claims announce the availability of Tissue Sparing Prostate Ablation (TSPA), known by its brand name as Encage. Encage uses a specific type of radiofrequency ablation (RFA), which basically cooks a tumor by keep reading

“Despite increasing adoption of active surveillance (AS) for low-risk prostate cancer, AS discontinuation rates are high, investigators report.” This quote, from a September 2021 Renal & Urology News report, referred to a study of over 16,000 Canadian prostate cancer (PCa) patients who had been diagnosed with low risk disease from 2008-2014. 51% of these patients keep reading

Men with localized prostate cancer (PCa) are usually given three treatment choices: radical prostatectomy (RP), external beam radiation therapy (EBRT) or Active Surveillance (AS). Although patients are rarely told about minimal-to-noninvasive treatments that can be applied as focal therapy... keep reading

Less than a year after we posted the original blog on the safety of testosterone replacement therapy (TRT) in the context of prostate cancer (PCa), a team from Baylor College of Medicine (Houston, TX) published the following statement: “The fears of [TRT] causing or worsening prostate cancer... keep reading

If you had prostate cancer (PCa) and opted to be treated with either prostatectomy (surgical removal) or whole-gland radiation, what sign of recurrence would you watch for? You’d be sure to have an annual PSA blood test. Why? Because after whole-gland treatment, it is expected that your PSA will drop to zero (or very close keep reading

Go online and do a search for “how to measure a wound.” You will find general principles, but you’ll also discover small variations in instructions on how to measure an open wound. How long is it? How wide? Are there irregular spaces below the skin surface or the floor of the wound where infection could keep reading